Abstract
As a result of the spread of SARS-CoV-2, a global pandemic was declared. Indiscriminate COVID-19 vaccination has been extended to include age groups and naturally immune people with minimal danger of suffering serious complications due to COVID-19. Solid immuno-histopathological evidence demonstrates that the COVID-19 genetic vaccines can display a wide distribution within the body, affecting tissues that are terminally differentiated and far away from the injection site. These include the heart and brain, which may incur in situ production of spike protein eliciting a strong autoimmunological inflammatory response. Due to the fact that every human cell which synthesises non-self antigens, inevitably becomes the target of the immune system, and since the human body is not a strictly compartmentalised system, accurate pharmacokinetic and pharmacodynamic studies are needed in order to determine precisely which tissues can be harmed. Therefore, our article aims to draw the attention of the scientific and regulatory communities to the critical need for biodistribution studies for the genetic vaccines against COVID-19, as well as for rational harm-benefit assessments by age group.
Acknowledgments
We would like to thank Prof. Arne Burkhard for his immense contribution in the field and we wish to express our deepest condolences to his family. Furthermore, we would like to thank Mr. Swen Gerards for his contribution as a concerned citizen.
Author contributions
Conceptualisation, P.P. and P.Am; writing-original draft preparation, P.P.; writing-review and editing, P.P., A.D., J.C.L, D.W., A.K., M.M., P.B., M.F., S.S., P.Am; supervision, P.P. and P.Am All authors have read and agreed to the published version of the manuscript.
Disclosure statement
The authors declare no conflict of interest.
Data availability
No data are associated with this article.